Grace Therapeutics (NASDAQ:GRCE) Trading Up 1.9% – Should You Buy?

Grace Therapeutics, Inc. (NASDAQ:GRCE)’s share price was up 1.9% during trading on Wednesday . The company traded as high as $4.75 and last traded at $4.36. Approximately 1,083,486 shares changed hands during trading, an increase of 28% from the average daily volume of 844,764 shares. The stock had previously closed at $4.28.

Analysts Set New Price Targets

A number of equities analysts have recently commented on GRCE shares. Wall Street Zen raised Grace Therapeutics to a “hold” rating in a report on Friday, January 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Grace Therapeutics presently has an average rating of “Hold” and a consensus price target of $12.00.

Grace Therapeutics Trading Up 1.9%

The firm has a market cap of $67.45 million, a P/E ratio of -10.90 and a beta of 0.68. The business has a 50-day moving average of $4.09 and a two-hundred day moving average of $3.58.

Grace Therapeutics (NASDAQ:GRCE) last issued its quarterly earnings data on Thursday, February 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). As a group, equities analysts expect that Grace Therapeutics, Inc. will post -1.06 EPS for the current year.

Institutional Investors Weigh In On Grace Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GRCE. SeaCrest Wealth Management LLC bought a new stake in Grace Therapeutics during the 3rd quarter worth $42,000. ADAR1 Capital Management LLC grew its position in shares of Grace Therapeutics by 98.4% in the 3rd quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock valued at $1,043,000 after buying an additional 173,823 shares during the last quarter. Stratos Wealth Partners LTD. bought a new stake in shares of Grace Therapeutics in the 4th quarter valued at about $39,000. Cerity Partners LLC bought a new stake in shares of Grace Therapeutics in the 4th quarter valued at about $1,463,000. Finally, Renaissance Technologies LLC grew its position in shares of Grace Therapeutics by 53.5% in the 4th quarter. Renaissance Technologies LLC now owns 129,781 shares of the company’s stock valued at $449,000 after buying an additional 45,220 shares during the last quarter. Institutional investors own 6.08% of the company’s stock.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.